Regenerx Biopharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.07.21	RegeneRx Issues Letter To Stockholders (PR Newswire)
14.07.21	RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome (PR Newswire)
01.07.21	RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement (PR Newswire)
28.06.21	RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement (PR Newswire)
13.06.18	RegeneRx Holds Annual Meeting (PR Newswire)
29.05.18	RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018 (PR Newswire)
02.05.18	ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO (PR Newswire)
25.04.18	GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops (PR Newswire)
09.04.18	RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome (PR Newswire)
14.03.18	RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds (PR Newswire)
12.03.18	RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy (PR Newswire)
02.03.18	RegeneRx Secures $1 Million in Funding (PR Newswire)
22.02.18	Key U.S. Dry Eye Patent Issued to RegeneRx (PR Newswire)
14.02.18	RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage (PR Newswire)
07.12.17	RegeneRx Releases Annual Letter to Shareholders (PR Newswire)
16.11.17	Tβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium (PR Newswire)
31.10.17	RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial (PR Newswire)
13.09.17	RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S. (PR Newswire)
31.08.17	RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia (PR Newswire)
30.08.17	RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017 (PR Newswire)
14.08.17	RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy (PR Newswire)
27.07.17	RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial (PR Newswire)
13.06.17	RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy (PR Newswire)
09.05.17	RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017 (PR Newswire)
13.03.17	RegeneRx Releases Annual Letter to Shareholders (PR Newswire)
27.02.17	RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S. (PR Newswire)
09.01.17	RegeneRx Receives Notice of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4. (PR Newswire)
16.12.16	RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4 (PR Newswire)
30.11.16	RegeneRx to Present at 9th Annual LD Micro Investor Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	122.95	1.49 %	K V
Alcon	77.26	1.34 %	K V
Lonza Grp	531.00	0.84 %	K V
Logitech Intl	72.44	0.33 %	K V
Zurich Insur Gr	553.80	0.33 %	K V
Swisscom	504.00	-0.98 %	K V
Geberit	520.80	-1.03 %	K V
ABB	49.41	-1.10 %	K V
Holcim	88.58	-1.34 %	K V
UBS Group	27.82	-1.87 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Regenerx Biopharmaceuticals IncShs

Aktien Top/Flop

Meistgelesene Nachrichten